Tasman Therapeutics
PrivateLast Round
Series A
Apr 3, 2025
Total Funding Raised
$175M
Company Overview
Tasman Therapeutics is a clinical-stage pharmaceutical company developing innovative treatments for neuropsychiatric disorders, including its lead product candidate R-107, an extended-release oral ketamine tablet for treatment-resistant depression.
Sector
Healthcare & Life Sciences
Verticals
Biotechnology, Mental Health, Clinical Trials
Business Model
B2B
Customer Profile
Services & Consulting
AI Layer
Non-AI
Keywords
Historical Pricing
Historical view of private secondary pricing and transaction trends.
Tasman Therapeutics Comparables
Compare Tasman Therapeutics with similar companies based on industry and business-model similarity.
| Company | Similarity | Market Cap |
|---|---|---|
| Neurocentrx Pharma | 91% | |
| HMNC Brain Health | 89% | |
| MIRA Pharmaceuticals, Inc. | 80% | |
Tasman Therapeutics Funding Rounds
Historical fundraising activity
| Round | Date | Amount Raised | Valuation | Investors | Sources |
|---|---|---|---|---|---|
| Series A | Apr 3, 2025 |
Market signals
Structured signals derived from secondary market and firmographic data.
- Apr 3, 2025
$175M round completed.
Tasman Therapeutics Filings
SEC and related filings with document metadata.
| Typed | Date | Amount Offered | Amount Sold | Filling | Pages | Download |
|---|---|---|---|---|---|---|
Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation |
Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation |
Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation |
Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation |
Frequently Asked Questions
Common questions about Tasman Therapeutics's valuation, stock price, and market status.